



FORM PTO-1449 (modified)

To: U.S. Department of Commerce

(PW FORM PAT-1449)

Patent and Trademark Office

Atty.

Dkt. No.

M#

Client Ref.

0280647

1992-30-0029CP1C2

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: ANDERSON et al.

Appln. No.: 09/911,703

Filing Date: July 25, 2001

Date: May 27, 2004

Page 1 of 1

Examiner: Schwadron, R. Group Art Unit: 1644

**U.S. PATENT DOCUMENTS**

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	AR						
	BR						
	CR						
	DR						
	ER						
	FR						
	GR						
	HR						

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	IR						
	JR						
	KR						
	LR						
	MR						
	NR						
	OR						
	PR						

**OTHER**

BS	QR	Idec Pharmaceuticals v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).
BS	RR	Biogen Idec v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).
	SR	
	TR	
	UR	
	VR	
	WR	
	XR	
	YR	
	ZR	
	AAR	

Examiner

Date Considered:

3/31/2005

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

Atty.  
Dkt. No.

M#

Client Ref.

0280647

1992-30-0029CP1C2

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: ANDERSON et al.

Appln. No.: 09/911,703

Filing Date: July 25, 2001

Examiner: Schwadron, R.

Group Art Unit: 1644

Date: March 18, 2004

Page 1

of

1

**U.S. PATENT DOCUMENTS**

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	MS	AR 5,595,721	01/1997	KAMINSKI et al.	—	—	
		BR 5,439,665	08/1995	HANSEN et al.	—	—	
		CR RE 38,008	02/2003	ABRAMS et al.	—	—	
		DR 5,736,137	04/1998	ANDERSON et al.	—	—	
		ER 5,776,456	07/1998	ANDERSON et al.	—	—	
		FR 5,843,439	12/1998	ANDERSON et al.	—	—	
		GR 6,399,061	06/2002	ANDERSON et al.	—	—	
		HR 6,682,734	01/2004	ANDERSON et al.	—	—	

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	IR	WO 94/11026	05/1994	PCT	ANDERSON et al.		
	JR						
	KR						
	LR						
	MR						

**OTHER**

MS	NR	Grossbard M.L., et al., "Monoclonal antibody-based therapies of leukemia and lymphoma," <i>Blood</i> , 1992, 80:863-878.
	OR	Tedder T.F., et al., "Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes," <i>Eur J Immunol</i> , 1986, 16(8):881-87.
	PR	Tedder T.F., et al., "Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19," <i>J Immunol</i> , 1988, 141(12):4388-94.
	QR	
	RR	
	SR	
	TR	
	UR	

Examiner

Date Considered:

3/31/2005

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	0280647	1992-30-0029CP1C2

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: ANDERSON *et al.*

Appln. No.: 09/911,703

Filing Date: July 25, 2001

Date: November 21, 2003 Page 1 of 1

Examiner: R. Schwadron Group Art Unit: 1644

**U.S. PATENT DOCUMENTS**

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
MS	AR	6,183,744 B1	02/2001	GOLDENBERG	—	—	
MS	BR	6,306,393 B1	10/2001	GOLDENBERG	—	—	
	CR						
	DR						
	ER						
	FR						

**FOREIGN PATENT DOCUMENTS**


	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	GR					
	HR					
	IR					
	JR					
	KR					
	LR					

**OTHER**

MS	MR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83.
	NR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, p. 271, Abstract No. 1051.
	OR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with 131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37<sup>th</sup> Annual Meeting</i> , p. 852, Abstract No. 622.
	PR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36.
	QR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, Abstract No. 1409.
	RR	Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp.1696-1711.
	SR	
	TR	
	UR	
	VR	

Examiner	Date Considered: 3/31/2003
----------	----------------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Atty. Dkt. No.	M#	Client Ref.
	037003-0280647	1992-30-0029CP1C2

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: Anderson, et al.

Appln. No.: 09/911,703

Filing Date: July 25, 2001

Date: October 21, 2003

Page 1 of 3

Examiner: Scwadron, R.

Group Art Unit: 1644

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
M/S	AR 5,500,362	03/1996	Robinson, et al.	435	7.23	
M/S	BR 5,648,267	07/1997	Reff	435	320.1	
	CR					

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclos	No
M/S	DR	0 125 023 A1	11/1984	EP	Cabilly, et al.				
	ER	0 125 023 B1	11/1984	EP	Cabilly, et al.				
	FR	0 125 023 B2	03/2002	EP	Cabilly, et al.				
	GR	0 173 494 A2	03/1986	EP	Morrison, et al.				
	HR	0 274 394 A2	07/1988	EP	Robinson, et al.				
	IR	0 274 394 A3	07/1988	EP	Robinson, et al.				
	JR	0 451 216 B1	01/1996	EP	Queen, et al.				
	KR	0 682 040 A1	11/1995	EP	Queen, et al.				
	LR	0 682 040 B1	11/1995	EP	Queen, et al.				
	MR	WO 88/04936	07/1988	WO	Robinson, et al.				
✓	NR	WO 92/07466	05/1992	WO	Hellström, et al.				


**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

M/S	Adams, R.A. et al., Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, <i>SB-2, Can Res</i> 28:1121-1125 (1968).				
↓	Adams, Richard, Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma, <i>Can. Res.</i> 27:2479-2482 (1967).				
	Anderson, K.C., et al., Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow, <i>Blood</i> 69(2):597-604 (1987)				
	Anderson, D.R., et al., Immunoreactivity and effector function associated with a chimeric anti-CD20 antibody, The Second Annual IBC International Conference on Antibody Engineering, Dec. 16-18, 1991.				
	Anderson, K.C., et al., Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation, <i>Blood</i> 63(6):1424-1433 (1984)				
	Appelbaum, F.R., Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. <i>Hem. Onc. Clinics of N.A.</i> 5(5):1013-1025 (1991).				
↓	Armitage, J.O. et al., Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP), <i>Cancer</i> 50:1695 (1982).				
✓	Bhan, A.K., et al., Stages of B cell differentiation in human lymphoid tissue, <i>J. Exp. Med.</i> , 154:737-749 (1981)				

*[Handwritten signature]*

3/31/2005





		Nadler, L.M., et al., Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma, <i>The Lancet</i> , Vol. II, pp. 427-431 (1984)				
		Nadler, L.M., et al., Serothrapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen, <i>Cancer Research</i> , 40:3147-3154 (1980)				
		Neuberger, M.S. et al., A hapten-specific chimaeric IgE antibody with human physiological effector function, <i>Nature</i> 314:268 (March 1985).				
		Oettgen, H.C., et al., Further biochemical studies of the human B-cell differentiation antigens B1 and B2, <i>Hybridoma</i> , 2(1):17-28 (1983)				
		Ozato, K., et al., Monoclonal antibodies to mouse MHC antigens III. Hybridoma antibodies reacting to antigens to the H-2 <sup>b</sup> haplotype reveal genetic control of isotype expression, <i>J. Immunology</i> , 126(1):317-321 (1981)				
		Press et al., Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas, <i>Blood</i> 69(2):584-591 (1987)				
		Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." <i>New England Journal of Medicine</i> 329/17: 1219-12223 (1993).				
		Press, O.W. et al., "Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, <i>J. Clin. Onc.</i> 7/8:1027-1038 (1989)				
		Reff, M., et al., Depletion of a B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20, <i>J. Cellular Biochem., Suppl.</i> 17E:260 (Abstract T103) (1993)				
		Reff, M., et al., Depletion of B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20, <i>Blood</i> , 83(2):435-445 (1994)				
		Robertson, M.J., et al., Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia, <i>Blood</i> , 79(9):2229-2236 (1992)				
		Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," <i>Hum. Antibod. Hybridomas</i> 2:84-93 (1991).				
		Sahagan et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, <i>J. Immunol.</i> 137:1066-1074 (1986).				
		Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, <i>Harvey Lectures</i> 69:125-143 (1974).				
		Schlom J., et al., Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy, <i>J. Natl. Cancer Inst.</i> , 82(9):763-771 (1990)				
		Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, <i>Nature</i> 276:269 (1978).				
		Smeland, E.B., et al., Activation of human B cells: Alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells, <i>J. Immunology</i> , 138(10):3179-3184 (1987)				
		Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, <i>Nucl. Med. Bio.</i> 18(6): 589-603 (1991).				
		Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, <i>Hybridoma</i> 5/1:517 (1986).				
		Tan et al., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, <i>J. Immunol.</i> 135:8564 (November 1985).				
		Tedder, T.F., et al., The B cell surface molecule B1 is functionally linked with B cell activation and differentiation, <i>J. Immunology</i> , 135(2):973-979 (1985)				
		Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." <i>Som. Cell &amp; Mol. Gen.</i> 12/6:555-566 (1986).				
		Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, <i>J. Biol. Chem.</i> 264(19):11282-11287 (1989).				
		Wessels, B.W., et al., Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies, <i>Med. Phys.</i> , 11(5):638-645 (1984)				

Examiner		Date Considered:	3/31/2005
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>			